Search

Data Analysis and Interpretation WG

Responsibilities:
Managing and analyzing data centrally. Planning and implementing the necessary infrastructure and data transfer agreements.

EHA-EBMT CAR T-cell Meeting

On this page, you can browse and/or download the 7th European CAR T-cell Meeting Sponsor Program. If the Sponsor Program does not display correctly, please click here or download the file.

Is TRTH for me?

Please see the eligibility criteria in the dropdown menu below.

Accommodation

Welcome to the Hotel Accommodation page for the EHA2025 Congress. Hotel Information and Official Housing Bureau

INTERPLAN AG is the official housing bureau for the EHA2025 Congress.

Implementation of the new EU Regulation for In Vitro Diagnostic Medical Devices: a ticking time bomb for the diagnostic sector.

May 28 2021

Urgent actions are needed now to prevent a collapse of diagnostic testing.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

Dec 13 2023

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).